ASCO GU 2026
Presentations Supported by Bayer
February 26-28, 2026
Agenda of oral and poster presentations at the 2026 Genitourinary (GU) Symposium of the American Society of Clinical Oncology (ASCO).
Please see below to download a PDF for each presentation and view a video (where applicable). Access for each publication will be available after the congress presentation.
Please select a compound to navigate to all related publications.
DAROLUTAMIDE
Efficacy and safety of darolutamide and ADT in patient subgroups by baseline comorbidities and concomitant medications: ARANOTE post hoc analyses
Date/Time: February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)
Session: Poster Session A: Prostate Cancer
Type: Poster
Presenting Author: Fred Saad
Poster Board Number: F7
Analysis of quality-adjusted time without symptoms or toxicity (Q-TWiST) in patients with metastatic hormone-sensitive prostate cancer: From the ARASENS trial
Date/Time: February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)
Session: Poster Session A: Prostate Cancer
Type: Poster
Presenting Author: Brigida Anna Maiorano
Poster Board Number: D14
Efficacy and safety of darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR): 52-week results from ARAMON
Date/Time: February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)
Session: Poster Session A: Prostate Cancer
Type: Poster
Presenting Author: Andrew Laccetti
Poster Board Number: E22
Real-world darolutamide safety and effectiveness in nonmetastatic castration-resistant prostate cancer (nmCRPC) by lipid-modifying agent use: Post hoc analyses of DAROL interim analysis 4 (IA4)
Date/Time: February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)
Session: Poster Session A: Prostate Cancer
Type: Poster
Presenting Author: Murilo Luz
Poster Board Number: C6
Androgen-Receptor pAthwAy inhibitors Triplet therapy (ARAAT): Real-world outcomes in metastatic hormone-sensitive prostate cancer
Date/Time: February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)
Session: Poster Session A: Prostate Cancer
Type: Poster
Presenting Author: Alicia K Morgans
Poster Board Number: B15
Real-world use of novel hormonal therapies in European and North American patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)
Date/Time: February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)
Session: Poster Session A: Prostate Cancer
Type: Poster
Presenting Author: Zdravko Vassilev
Poster Board Number: B19
Impact of hospitalizations on health-related quality of life and overall survival in metastatic castration-sensitive prostate cancer: Insights from the ARANOTE trial
Date/Time: February 27, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)
Session: Poster Session B: Prostate Cancer and Urothelial Carcinoma
Type: Poster
Presenting Author: Alicia K Morgans
Poster Board Number: A16
Safety Profile of Darolutamide + ADT compared to Enzalutamide, Apalutamide, and Abiraterone in metastatic castration-sensitive prostate cancer: Results from the First Safety Matching-Adjusted Indirect Comparison
Date/Time: February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)
Session: Poster Session A: Prostate Cancer
Type: Poster
Presenting Author: Neal Shore
Poster Board Number: D18
Harnessing caregiver support to improve shared decision-making in metastatic prostate cancer treatment: A US-based quantitative survey
Date/Time: February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)
Session: Poster Session A: Prostate Cancer
Type: Poster
Presenting Author: Daniel George
Poster Board Number: D12
Novel androgen receptor inhibitors for the treatment of metastatic castration-sensitive prostate cancer: A cost-effectiveness analysis
Date/Time: February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)
Session: Poster Session A: Prostate Cancer
Type: Poster
Presenting Author: William V Padula
Poster Board Number: G5
Discontinuation Rates Among Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) initiating novel androgen receptor inhibitors in Oncology and Non-Oncology settings
Date/Time: February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)
Session: Poster Session A: Prostate Cancer
Type: Poster
Presenting Author: Hannus McManus
Poster Board Number: C12
A phase 2 trial of darolutamide to enhance prostate-specific membrane antigen expression in patients with localized prostate cancer (Daro-PET)
Date/Time: February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)
Session: Poster Session A: Prostate Cancer
Type: Poster
Presenting Author: Jose Mauricio Mota
Poster Board Number: K2
Impact of age, number of cycles of chemotherapy and presence of visceral metastases on PSA response in patients on triplet therapy (ADT + Darolutamide + Docetaxel) for mHSPC: UK real world data from the RECOMMEND study
Date/Time: February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)
Session: Poster Session A: Prostate Cancer
Type: Poster
Presenting Author: Amit Bahl
Poster Board Number: A26
3-Weekly Docetaxel 75 mg/m2 vs 2-Weekly Docetaxel 50 mg/m2 in Combination with Darolutamide + ADT in Patients with mHSPC : Subgroup Analyses from the Randomised Phase 3 ARASAFE Trial
Date/Time: February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)
Session: Poster Session A: Prostate Cancer
Type: Poster
Presenting Author: Marc-Oliver Grimm
Poster Board Number: E8
Prognostic significance of depressive symptoms in men with advance prostate cancer (PC): Results from the IRONMAN registry
Date/Time: February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)
Session: Poster Session A: Prostate Cancer
Type: Poster
Presenting Author: Elizabeth Tran
Poster Board Number: D20
Sequencing of therapeutic agents before and after metastatic castration-resistant prostate cancer (mCRPC) diagnosis in an international real-world setting
Date/Time: February 26, 2026 | 11:30 AM -12:45 PM; 5:45 PM - 6:45 PM (PST)
Session: Poster Session A: Prostate Cancer
Type: Poster
Presenting Author: Rana R McKay
Poster Board Number: C7
RADIUM-223
Final Overall Survival Results from the EORTC 1333/PEACE-3 Trial: Enzalutamide With or Without Radium-223 in Metastatic Castration-Resistant Prostate Cancer
Date/Time: February 26, 2026 | 8:15 - 8:25 AM (PST)
Session: Oral Abstract Session A: Prostate Cancer
Type: Oral
Presenting Author: Enrique Gallardo
Abstract Number: 15
Long-Term Outcomes With Radium-223 in Metastatic Castration Resistant Prostate Cancer: US Patient Subset of the 10-Year REASSURE Global Study
Date/Time: February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)
Session: Poster Session A: Prostate Cancer
Type: Poster
Presenting Author: Celestia Higano
Poster Board Number: B18
Real-world characteristics of long-term survivors with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): An analysis of the global REASSURE study
Date/Time: February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)
Session: Poster Session A: Prostate Cancer
Type: Poster
Presenting Author: Saby George
Poster Board Number: B7
Genomic profiling in circulating tumor DNA from a multicenter prospective study of radium-223 in bone-metastatic castration-resistant prostate cancer: the KYUCOG-1901 study
Date/Time: February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)
Session: Poster Session A: Prostate Cancer
Type: Poster
Presenting Author: Masaki Shiota
Poster Board Number: H4
Radium 223 without Androgen Deprivation Therapy (ADT) in Patients (Pts) with Biochemically Recurrent Prostate Cancer (BCR) and PET Findings in the Bones
Date/Time: February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)
Session: Poster Session A: Prostate Cancer
Type: Poster
Presenting Author: Melissa L Abel
Poster Board Number: G1
Circulating tumor DNA (ctDNA} dynamics in bone-dominant metastatic castration resistant prostate cancer (mCRPC} treated with radium-223 with or without olaparib: Biomarker analyses from the multicenter, randomized, phase 2, investigator-initiated COMRADE trial
Date/Time: February 26, 2026 | 11:30 AM – 12:45 PM; 5:45 PM – 6:45 PM (PST)
Session: Poster Session A: Prostate Cancer
Type: Poster
Presenting Author: Rana R. McKay
Poster Board Number: E13
PIPELINE
First-in-human assessment of actinium-225-prostate-specific membrane antigen (225Ac-PSMA)-Trillium (BAY 3563254) in mCRPC: Dose-escalation results of the Phase 1 PAnTHa study
Date/Time: February 26, 2026 | 5:00 PM PM – 5:45 PM (PST)
Session: Rapid Oral Abstract Session A: Prostate Cancer
Type: Oral
Presenting Author: Fred Saad
Abstract #19
The compendium provided by Bayer is a compilation of Presentations Sponsored by Bayer & Presentations from Bayer-supported Investigator-Initiated Research. Copies of presentations obtained from this compendium are for personal use only and may not be reproduced or distributed without permission from The American Society of Clinical Oncology (ASCO) and from the authors. The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Reused with permission. © 2026 American Society of Clinical Oncology (ASCO). All rights reserved.
For any questions, please contact Medical Information at 1-888-84-BAYER (1-888-842-2937), or visit go.bayer.com/vPIR
© 2026 Bayer. All rights reserved. Bayer and the Bayer Cross are registered trademarks of Bayer. 100 Bayer Boulevard, PO Box 915, Whippany, NJ 07981 USA. 2/26
MA-M_DAR-US-0390-1
MA-M_DAR-US-0391-1